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Background and Purpose: The benefit of thrombolysis in ischemic stroke patients
without a visible vessel occlusion still requires investigation. This study tested the
hypothesis that non-lacunar stroke patients with no visible vessel occlusion on baseline
imaging would have a favorable outcome regardless of treatment with alteplase.
Methods: We utilized a prospectively collected registry of ischemic stroke patients [the
International Stroke Perfusion Imaging Registry (INSPIRE)] who had baseline computed
tomographic perfusion and computed tomographic angiography. The rates of patients
achieving modified Rankin Scale (mRS) 0–1 were compared between alteplase treated
and untreated patients using logistic regression to generate odds ratios.
Results: Of 1569 patients in the INSPIRE registry, 1,277 were eligible for inclusion.
Of these, 306 (24%) had no identifiable occlusion and were eligible for alteplase, with
141 (46%) of these patients receiving thrombolysis. The treated and untreated groups
had significantly different median baseline National Institutes of Health Stroke Scale
(NIHSS) [alteplase 8, interquartile range (IQR) 5–10, untreated 6, IQR 4–8, P < 0.001]
and median volume of baseline perfusion lesion [alteplase 5.6mL, IQR 1.3–17.7mL,
untreated 2.6mL, IQR 0–6.7mL, P < 0.001]. After propensity analysis, alteplase treated
patients without a vessel occlusion were less likely to have an excellent outcome
(mRS 0–1; 56%) than untreated (78.8%, OR, 0.42, 95% confidence interval, 0.24–0.75,
P = 0.003).
Conclusions: In this non-randomized comparison, alteplase treatment in patients
without an identifiable vessel occlusion did not result in higher rates of favorable outcome
compared to untreated. However, treated patients displayed less favorable baseline
prognostic factors than the untreated group. Further studies may be required to confirm
this data.
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INTRODUCTION
Alteplase has been shown to be an effective therapy for ischemic
stroke patients when administered within 4.5 h of symptom onset
(1–4). However, up to 39% of patients presenting with clinical
symptoms with an ischemic stroke have no identifiable vessel
occlusion on baseline computed tomographic (CT) angiography
(CTA) (5, 6). There are several possible reasons which may result
in patients presenting to hospital with the clinical symptoms
suggestive of a stroke but with no identifiable vessel occlusion
on CTA. These include spontaneous recanalization of a recent
occlusion such that no occlusion exists at the time of scanning
despite one having been previously present, small and/or
distal occlusion beyond the resolution of CTA, hemodynamic
infarction without vessel occlusion or a non-stroke cause of an
acute focal neurological deficit (7).
The efficacy of alteplase to treat patients without an
identifiable vessel occlusion on baseline vascular imaging is
controversial (6, 8–11), with some studies demonstrating that
such patients may have no better clinical outcome after alteplase
(6, 8, 9). An individual patient meta-analysis of alteplase-treated
patients suggests the sub-group of patients with mild baseline
stroke severity do have a higher odds of favorable outcome after
alteplase compared to placebo-treated patients (3). However,
the placebo-controlled trials included in the meta-analysis were
performed without imaging based patient selection, instead
of using only a noncontrast computed tomography (NCCT),
meaning that the vessel occlusion status in these patients with
mild symptoms is unknown (12). Patients without a baseline
occlusion or a perfusion lesion are now often excluded from
trials of reperfusion therapy, as identifying a reperfusion therapy
“target” improves the likelihood of detecting clinical changes
between study groups (13, 14). This is due, in part, to the poor
natural history of stroke in patients with an identifiable large
vessel occlusion who do not undergo recanalization. Conversely,
the natural history of patients without an identifiable vessel
occlusion may be very good, and as such there is a ceiling effect
for reperfusion therapy in these patients where a high proportion
have an excellent clinical outcome without intervention.
Whilst multimodal CT is a powerful tool to predict the clinical
outcomes of patients after alteplase therapy (15–17), previous
work has also identified subgroups of patients who do not benefit
from alteplase or where outcomes may be unfavorable (18, 19).
In the present study, we hypothesized that non-lacunar ischemic
stroke patients with no visible baseline vessel occlusion on CTA
will not show higher rates of excellent clinical outcome [modified
Rankin Scale (mRS) 0–1] at 90 days after alteplase therapy when




Ischemic stroke patients presenting to hospital within 12 h of
symptom onset were prospectively recruited to the International
Stroke Perfusion Imaging Registry (INSPIRE) in participating
centers. Contributing to this cohort were seven hospitals across
Australia, China, Canada between 2011 and 2014. Patients
underwent pre-treatment multimodal CT imaging, including
NCCT, CT perfusion (CTP), CT angiography, and follow-up
magnetic resonance imaging (MRI) performed at 24-h post
stroke. The National Institutes of Health Stroke Scale (NIHSS)
was used at baseline to assess clinical severity. Intravenous
thrombolysis was administered to patients according to local
guidelines and the clinical judgment of the treating physician.
For the current study, we restricted our analyses to patients
potentially eligible for thrombolysis therapy who presented to the
hospital within 4.5 h of onset. In addition to standard clinical
and NCCT criteria all patients had multimodal CT prior to
treatment, and this information was used by the local treating
neurologists as decision assistance at the individual patient level
for alteplase eligibility (19). Based on standard NCCT criteria,
patients were not eligible for alteplase treatment if they had
an intracranial hemorrhage or extensive early ischemic change.
In addition, an unfavorable pattern on baseline CTP: small
or no identifiable perfusion lesion, a large ischemic core, a
lack of perfusion lesion-core mismatch (18, 19) or lack of a
vessel occlusion along with perfusion lesion size and clinical
characteristics would have been taken into consideration by the
treating neurologist in determining a decision to administer
alteplase. Thus, in some patients, alteplase treatment may have
been withheld at the attending neurologists’ discretion based on
clinical and radiological characteristics.
The mRS assessed the degree of dependence and disability
at 90 days after stroke. Endovascular therapy was not available
at all the study centers during INSPIRE recruitment between
2011-2014. The INSPIRE study was approved by the Hunter
New England Health District ethics committees in accordance
with Australian NHMRC guidelines. All patients in the registry
provided written consent in accordance with the Declaration of
Helsinki. For this study, patients within the INSPIRE registry
were required to have complete baseline clinical characteristics,
including baseline NIHSS score and stroke onset time, baseline
CTP and CTA imaging, and 3-month mRS score. The INSPIRE
registry did not include patients who had a Transient Ischemic
Attack, if the patient had a brief episode of neurologic
dysfunction, and had no acute infarction on the follow-up
imaging (20).
Baseline Imaging
The baseline CT imaging included brain NCCT, CTP, and CTA,
gained with different CT scanners (64-, 128-, 256-, or 320-
detectors, with Toshiba, Siemens, GE, or Philips scanners). Axial
coverage ranged from 40 to 160mm. After CT perfusion, a CTA
was acquired from the aortic arch to vertex (12). The details of
each scanner are summarized in Supplementary Table 1.
Follow-Up Imaging
All the treated and non-treated patients underwent a magnetic
resonance imaging (MRI), using 1.5 Tesla or 3 Tesla scanner
between 24 and 48 h post-stroke. The MRI protocol included
an axial gradient-echo T2∗-weighted series, diffusion-weighted
image (DWI), perfusion-weighted image (PWI), MR time of
flight angiography, as well as fluid-attenuated inversion recovery
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imaging. A follow-up NCCT and CTP was performed using the
above protocols when MR was not available, or the patient had
contraindications to MRI.
Image Post-processing and Classification
of Patients
Baseline arterial occlusion status was assessed visually on CTA by
three stroke neurologists. All baseline CTA scans were analyzed
using maximum intensity projection (MIP) technique in the core
laboratory for occlusion site and severity using the thrombolysis
in cerebral infarction (TICI) grading system. We classified
baseline vessel occlusion status as either (i) normal = TICI 3,
(ii) partial= TICI 2a or 2b, or (iii) complete= TICI 1 or 0.
The baseline CTP images were analyzed by the treating
clinician before treatment decision, however, the results were
not recorded. Therefore, the research team analyzed the baseline
and follow-up CTP images retrospectively. Both clinician and
the research team used the same commercial software, MIStar
(Apollo Medical Imaging Technology, Melbourne, Australia)
(21). The threshold for perfusion lesion was defined as a relative
delay time (DT) >3 s, and the ischemic core was defined as
relative cerebral blood flow (rCBF) <30% within the perfusion
lesion (22). Reperfusion was defined as a reduction of the acute
perfusion lesion of >80% from the acute to the 24-h perfusion
imaging perfusion lesion of zero. Hemorrhagic transformation
(HT) was classified based on morphological appearance on
follow-up imaging (23) as either hemorrhagic infarction type 1
or 2 (HI1: small petechiae, HI2: more confluent petechiae) or
parenchymal hematoma type 1 or 2 (PH1: 30% of the infarcted
area with mild space-occupying effect, PH2: 30% of the infarcted
area with significant space-occupying effect), and symptomatic
intracerebral hemorrhage (sICH) was defined as hemorrhage
with NIHSS change≥4 from baseline to 24-h or leading to death
by stroke neurologists blinded to treatment and pre-treatment
imaging information.
Statistical Analysis
Statistical analyses were programmed using Stata (v13.0;
StataCorp LP, College Station, TX). The aim of this study was
to examine the clinical and imaging outcomes of alteplase-
eligible patients without a vessel occlusion who were treated with
alteplase compared to those who had not been treated. Patients
were divided into two groups based on their baseline vessel
patency status: no visible vessel occlusion (normal) or visible
vessel occlusion (including partial and complete occlusion).
Patients without an occlusion were further divided into two
subgroups based on the volume of perfusion lesion: these were
patients with perfusion lesions <15mL and those with perfusion
lesions >15mL. The baseline clinical and imaging variables
between treated and untreated patients in the no-occlusion
group were compared using a two-sample t-test, Wilcoxon
signed-rank sum test, Kruskal-Wallis, and Fisher’s exact tests,
where applicable. Additionally, we used Wilcoxon rank-sum test
to assess the differences of the NIHSS improvement between
treatment groups in patients without a vessel occlusion, and then
in patients with a vessel occlusion.
Next, we used inverse propensity score weighting (IPSW) to
adjust the baseline bias of variables between the two treatment
groups, using this method could enforce the model to use a
balanced dataset by gaining the different amount of information
from each patient. The IPSW method has three steps. First,
we used a logistic regression model to generate a propensity
score for each patient, which provides the probability of a
patient receiving alteplase treatment according to their baseline
characteristics. The outcome of this propensity score generating
model was treatment with alteplase (binary outcome, treated
vs. untreated), and we used age, baseline NIHSS, onset time to
imaging, baseline volume of perfusion lesion, and center (John
Hunter Hospital vs. other hospitals) to control the model for
confounding. Second, we calculated the inverse probability of
receiving thrombolysis or not from the propensity score. Last,
we used the inverse probabilities as weights in the final logistic
regression model for each patient, to measure the relative risk for
treatment with alteplase in patients without a vessel occlusion.
We calculated the absolute standardized difference for each
baseline variables before and after propensity score matching,
to check the baseline bias of treated and untreated groups. The
outcomes in the final logistic regression model were: Excellent
(mRS 0–1 vs. 2–6), Good (mRS 0–2 vs. 3–6), and Poor (mRS 5–
6 vs. 0–4). The propensity analysis was applied to patients who
had visible baseline vessel occlusion, patients who had no visible
baseline vessel occlusion, as well as the two no vessel occlusion
subgroups, perfusion lesions <15mL and perfusion lesions
>15mL.
Furthermore, an additional sensitivity analysis was performed
for patients who had no visible vessel occlusion using regression
adjustment with the propensity score. Multivariable logistic
regression was performed to assess the effect of alteplase
treatment and baseline vessel occlusion status, covariates
included age, baseline NIHSS score, onset time to imaging,
baseline volume of perfusion lesion, center, and the interaction
term of baseline vessel occlusion status and treatment.
RESULTS
At the time of this analysis, the INSPIRE registry contained
1,569 patients. Two hundred and ninety two patients were not
eligible for analysis: 134 patients were excluded because they
were given alteplase outside the 4.5-h time window, 28 patients
had poor quality baseline imaging due to motion artifacts, 89
untreated patients had documented clinical contraindications
to thrombolysis (e.g., rapid clinical improvement, premorbid
disability, or major early ischemic change on NCCT), and 41
patients with lacunar strokes on follow-up MRI were excluded.
Of the remaining 1,277 patients who were clinically eligible for
thrombolysis, 306 (24%) had no vessel occlusion at baseline (TICI
3) compared to 971 (76%) who had a vessel occlusion (TICI
0-2b). Of the patients without a baseline occlusion and eligible
for thrombolysis, 141 (46%) were treated with alteplase, and 165
(54%) were not treated. In comparison, of those patients with a
baseline occlusion, 732 (75%) received alteplase, and 239 (25%)
did not treat.
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Of the patients without a baseline occlusion, alteplase treated
patients had highermedian baseline NIHSS score (8, interquartile
range (IQR) 5–10 for treated vs. 6, IQR 4–8 for untreated
patients, P < 0.001) and larger median perfusion lesions (5.6mL,
IQR 1.3–17.7mL for treated vs. 2.6mL, IQR 0–6.7mL for
untreated patients, P < 0.001, Table 1). The baseline imbalances
between alteplase treated and untreated groups were reduced
after propensity score matching (Supplementary Tables 2, 3).
Patients without a vessel occlusion at baseline who were treated
with alteplase had reduced odds of achieving an excellent or
good 90-day clinical outcome than patients who were not
treated [mRS 0–1, alteplase 56%, untreated 79%, odds ratio
(OR) 0.36, 95% confidence interval (CI) 0.22–0.59, P < 0.001;
mRS 0–2, alteplase 68%, untreated 88%, OR 0.31, 95% CI 0.17–
0.56, P < 0.001, Table 2, Figure 1] even following propensity
matching (mRS 0–1, OR 0.42, 95% CI 0.24–0.75, P = 0.003;
mRS 0–2, OR 0.41, 95% CI 0.21–0.81, P = 0.010, Table 2).
Both sensitivity analysis and results frommultivariable regression
with an interaction term of baseline vessel occlusion status and
treatment yielded similar results (Supplementary Tables 4, 5).
Additionally, alteplase treated patients with no vessel occlusion
had an increased odd of poor clinical outcome than untreated
patients (mRS 5–6, alteplase 9%, untreated 1%, OR 7.58, 95% CI
1.67–34.48, P = 0.009), however this was no longer significant
following propensity matching (mRS 5–6, OR 3.09, 95% CI 0.50–
19.01, P = 0.223, Table 2). Lastly, all the patients who had no
visible baseline occlusion and 24-h perfusion imaging available
had complete reperfusion (n= 69, Table 1).
A total of 14 patients without a vessel occlusion had a
hemorrhagic transformation on follow-up imaging, all of whom
were treated with alteplase (9.9% of all alteplase treated non-
occlusion patients, 6 HI1, 1 HI1, 3 PH1, and 4 PH2). The rate
of HI1 and PH2 was significantly higher in alteplase treated
patients without a vessel occlusion compared to untreated (HI1,
alteplase 4.3%, untreated 0%, P = 0.009; PH2, alteplase 2.8%,
untreated 0%, P = 0.044, Table 1). There were 3 non-occlusion
patients with sICH, all of whom were treated (sICH, alteplase
2.1%, untreated 0%, P = 0.097). Of the 14 patients with any
TABLE 1 | Clinical and imaging characteristics of patients with and without a visible baseline occlusion who were also clinically eligible for alteplase therapy.
Visible baseline occlusion P-value No visible baseline occlusion P-value
Total Treated Untreated Treated Untreated
N = 1277 N = 732 N = 239 N = 141 N = 165
Age, mean (SD), y 70.7 (13.9) 72.0 (12.5) 70.4 (16.0) 0.109 68.1(14.4) 67.5 (15.2) 0.714
NIHSS, median (IQR) 12 (8 to 17) 14 (10 to 18) 13 (10 to 17) 0.015 8 (5 to 10) 6 (4 to 8) <0.001
Onset to imaging, median (IQR),
min
120 (80 to 160) 121 (91 to 157) 150 (81 to 163) 0.120 89.1 (46.5 to 139) 98.5 (58 to 159) 0.099
Perfusion lesion volume, median
(IQR), mL
61.7 (15.5 to 129.2) 97.0 (52.5 to 148.0) 60.1 (33.0 to 137.1) <0.001 5.6 (1.3 to 17.7) 2.6 (0 to 6.7) <0.001
Ischemic core volume, median
(IQR), mL
12.9 (2.7 to 37.0) 19.8 (8.2 to 54.1) 16.9 (8.3 to 51.8) 0.418 1.8 (0.1 to 6.4) 0.4 (0 to 1.9) <0.001
Reperfusion, n (%) 332 (54.4) 280 (49.8) 55 (44.7) 0.326 33 (100) 36 (100) –
NIHSS improvement, median
(IQR)
– 4 (24 to −17) 3 (15 to −6) 0.008 4 (13 to −3) 4 (17 to −8) 0.913
Any HT, n 172 146 (19.9) 12 (5) <0.001 14 (9.9) 0 (0) <0.001
HI1, n (%) 58 49 (6.7) 3 (1.3) <0.001 6 (4.3) 0 (0) 0.009
HI2, n (%) 39 34 (4.6) 4 (1.7) 0.052 1 (0.7) 0 (0) 0.461
PH1, n (%) 38 34 (4.6) 1 (0.4) 0.001 3 (2.1) 0 (0) 0.097
PH2, n (%) 37 29 (4.0) 4 (1.7) 0.102 4 (2.8) 0 (0) 0.044
sICH, n (%) 28 22 (3.0) 3 (1.3) 0.163 3 (2.1) 0 (0) 0.097
Values are presented as means with standard deviation (SD), medians with inter-quartile range (IQR), or number (%). NIHSS, National Institutes of Health Stroke Scale; HT, hemorrhagic
transformation; HI, hemorrhagic infarction; PH, parenchymal hematoma; sICH, symptomatic intracerebral hemorrhage.
TABLE 2 | The effect of alteplase treatment in patients without a visible vessel occlusion (TICI 3).
Outcome (% treated/% untreated) Without propensity analysis P-value Propensity analysis P-value
OR 95% CI OR 95% CI
Excellent (56/79) 0.36 0.22 to 0.59 <0.001 0.42 0.24 to 0.75 0.003
Good (68/88) 0.31 0.17 to 0.56 <0.001 0.41 0.21 to 0.81 0.010
Poor (9/1) 7.58 1.67 to 34.48 0.009 3.09 0.50 to 19.01 0.223
The results are from logistic regression models without and with propensity analysis. OR, odds ratio; CI, confidence interval.
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HT, 9 of them had baseline perfusion deficits <15mL, and 2
of the 3 patients with sICH had <15mL perfusion deficits at
baseline.
After propensity score adjustment, alteplase treated patients
without a vessel occlusion and perfusion lesions <15mL had
lower rates of excellent or good outcome compared to untreated
patients (mRS 0–1, alteplase 63%, untreated 81%, OR 0.51, 95%
CI 0.27–0.94, P = 0.031; mRS 0–2, alteplase 72%, untreated 91%,
OR 0.40, 95% CI 0.19–0.86, P = 0.018, Table 3). Additionally,
the alteplase treated patients without a baseline vessel occlusion
and perfusion lesions <15mL had more frequently had poor
outcomes compared to untreated patients (mRS 5–6, alteplase
6%, untreated 0%, Table 3). Similarly, the rate of excellent
or good outcome was not higher in alteplase treated patients
without a vessel occlusion and perfusion lesions >15mL (mRS
0–1, alteplase 38%, untreated 53%, OR 0.17, 95% CI 0.04–0.73,
P = 0.017; mRS 0–2, alteplase 58%, untreated 60%, OR 0.34, 95%
CI 0.08–1.49, P = 0.151), however, the rate of poor outcome did
not differ between groups (mRS 5–6, alteplase 15%, untreated
13%, OR 1.48, 95% CI 0.18–11.90, P = 0.715, Table 3).
FIGURE 1 | mRS distribution of ischemic stroke patients without a visible
vessel occlusion, who were or were not treated with alteplase. mRS, modified
Rankin Scale.
As expected, patients with a vessel occlusion at baseline had
a trend toward higher odds of achieving an excellent or a
good outcome at 90-day when treated with alteplase (mRS 0-
1, alteplase 37%, untreated 30%, OR 1.36, 95% CI 0.99–1.86,
P = 0.058; mRS 0–2, alteplase 52%, untreated 46%, OR 1.25, 95%
CI 0.93–1.67, P = 0.142, Table 4, Figure 2). This became highly
significant after propensity analysis (mRS 0–1, OR 1.84, 95%
CI 1.32–2.58, P < 0.001; mRS 0–2, OR 1.71, 95% CI 1.25–2.32,
P = 0.001, Table 4).
DISCUSSION
We observed that patients without a baseline vessel occlusion
who, based on standard clinical and NCCT criteria (and treating
neurologists prior knowledge of CTA and CTP profiles), receive
alteplase therapy, showed significantly lower odds of favorable
clinical outcome compared to a population of patients not treated
with alteplase where the treating neurologist also was aware
of the patients CTA and CTP profiles. The natural history of
FIGURE 2 | mRS distribution of ischemic stroke patients with a visible vessel
occlusion, who were or were not treated with alteplase. mRS, modified Rankin
Scale.
TABLE 3 | The effect of alteplase treatment in patients without a vessel occlusion grouped by the volume of perfusion lesions, logistic regression results with propensity
analysis.
Outcome Perfusion lesions <15 mL P-value Perfusion lesion >15 mL P-value
% treated/% untreated OR 95% CI % treated/% untreated OR 95% CI
Excellent 63/81 0.51 0.27–0.94 0.031 38/53 0.17 0.04–0.73 0.017
Good 72/91 0.40 0.19–0.86 0.018 58/60 0.34 0.08–1.49 0.151
Poor 6/0 – – – 15/13 1.48 0.18–11.90 0.715
OR, odds ratio; CI, confidence interval.
TABLE 4 | The effect of alteplase treatment in patients with a visible vessel occlusion (TICI 0-2b).
Outcome (% treated/% untreated) Without propensity analysis P-value Propensity analysis P-value
OR 95% CI OR 95% CI
Excellent (37/30) 1.36 0.99–1.86 0.058 1.84 1.32–2.58 <0.001
Good (52/46) 1.25 0.93–1.67 0.142 1.71 1.25–2.32 0.001
Poor (24/23) 1.05 0.74–1.49 0.774 0.74 0.51–1.06 0.097
The results are from logistic regression models without and with propensity analysis. OR, odds ratio; CI, confidence interval.
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patients without a vessel occlusion, where the decision was made
by the clinical team not to treat resulted in 79% of untreated
patients being functionally independent at 90 days. Importantly,
however, this still leaves 21% of patients with disability at 90 days
indicating that some form of treatment is warranted. However,
by comparison, patients without a vessel occlusion who were
treated with alteplase had a lower rate of excellent clinical
outcome (56%) at 90 days. Importantly, in patients without a
baseline vessel occlusion who were treated with alteplase, the
rate of hemorrhage was significantly higher than those who were
not treated. Therefore, the risk of hemorrhage after alteplase
treatment might be the reason for the observed higher rate of
poor outcome in treated patients. Our results are consistent
with previous observational studies, suggesting that treatment of
patients with no baseline occlusion with alteplase are less likely
to be of benefit (6, 8, 9), while exposing patients to the risk
of hemorrhage (18). Taken together, the lower rate of excellent
outcome and increased risk of hemorrhage as a result of alteplase
therapy in patients without a baseline vessel occlusion indicate
that a safer thrombolytic is required which would target the 21%
of patients who were not disability-free at 90 days.
Patients included in the study had milder stroke severity at
baseline compared to studies designed to test the efficacy of
alteplase on ischemic stroke patients (11). This is a critical point
because it highlights a difference between an observational study
and the clinical trials that validated the use of thrombolysis. Our
study includes many patients who may have been considered
too mild to be enrolled in clinical trials designed to measure
alteplase effectiveness. This milder stroke population within
INSPIRE has contributed to our ability to show a significant
difference between our study populations, both with and without
propensity analysis. The study included a large proportion of
patients without a vessel occlusion and perfusion lesion <15mL
(82%), a subgroup previously reported to gain no net benefit from
alteplase therapy (18). We have noted a similar lack of benefit in
the subgroup of patients without a vessel occlusion and perfusion
lesion >15mL, suggesting patients without a vessel occlusion are
less likely to be of benefit from alteplase treatment, regardless of
the volume of baseline perfusion lesion. However, it is important
to note the relatively small numbers of patients with perfusion
lesion volumes above 15mL and the possibility that some patients
included in this study without a baseline occlusion may have
spontaneously recanalized before baseline imaging. Potentially
the latter are patients with a relatively the high risk of hemorrhage
with alteplase therapy. This notion is supported by the data that
all patients without a baseline occlusion showed reperfusion at
24 h, regardless of alteplase therapy.
Some study limitations require acknowledgment. (1) Given
the observational design, there were significant differences
between baseline characteristics of patients treated and untreated
with alteplase across all the study groups in terms of their baseline
clinical severity which may have skewed the results toward
favoring the untreated patient group even after propensity
adjustment. (2) The differences in baseline characteristics
between the treated and untreated patients without a baseline
vessel occlusion will likely have contributed the worse outcomes
in the treated patients, however measuring any clinical
improvement in this cohort will be difficult due to an excellent
natural history. (3) It is challenging to assess the M3 and
M4 occlusions, however, we found patients who had no vessel
occlusion, had minimal perfusion lesion volumes which were not
in the distal territories, were reperfused on 24-h imaging and had
minimal DWI lesion volumes. This suggests that patients in this
study were more likely to have spontaneously recanalized, since
there was no acute radiological treatment target and minimal
clinical deficit at 24 h. (4) It appears the INSPIRE site neurologists
were reasonably adept at identifying patients with a favorable
natural history and thus withholding treatment even when they
appeared to fullfil standard clinical criteria for thrombolysis.
However, due to the database design, we have not captured all
the information that led to the treating neurologists avoiding
thrombolysis in such patients and unmeasured confounding
variables are also possible influences. Indeed, it may be difficult
to measure some influences on clinician behaviors such as
perceptions of patient frailty or other impressions related to
an end of the bed “gestalt” assessment of the patient and their
imaging. (5) INSPIRE is a large study and sites are strongly
encouraged to enroll consecutive patients, the need for pre-
treatment multimodal CT and follow-up MR, along with clinical
data from several time-points means that not all treated or
untreated patients at every center are included, which may bias
our sample against generalizability. (6) There may be variables
presented which INSPIRE has not captured which may be of
relevance to the results, such as patient frailty or undocumented
comorbidities. (7) We understand that the mRS at 90-day were
assessed by different clinicians across sites, which may influence
the interpretation of our data. Therefore, we dichotomized the
mRS outcomes to Excellent (mRS 0–1 vs. 2–6), Good (mRS 0–
2 vs. 3–6), and Poor (mRS 5–6 vs. 0–4), which may potentially
reduce the influence of different jurisdictions on our data
compared to treating the mRS outcome as an ordinal variable.
8) This study assessed only a single time point with perfusion
imaging, repeated measures may be an ideal method to capture
dynamic changes in cerebral blood flow to assess if patients had
spontaneous recanalization. (9) The data presented is hypothesis
generating and cannot replace a randomized clinical trial.
CONCLUSIONS
This study suggests that patients without a vessel occlusion may
be less likely to have clinical improvement due to alteplase
therapy. This may very likely represent a treatment selection bias,
however and there is currently no evidence that alteplase should
be withheld in this group of patients. An alternative thrombolytic
agent may be ideal in patients without a baseline vessel occlusion
in order to reduce the hemorrhage rate and reduce the rate
of long-term disability in patients which a clinical belief that
treatment is required.
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